Pidotimod vs HNP-1
Head-to-head comparison of Pidotimod (3-L-Pyroglutamyl-L-Thiazolidine-4-Carboxylic Acid) and HNP-1 (Human Neutrophil Peptide 1 (Alpha-Defensin 1)) — benefits, dosing, side effects, research data, and where to buy.
| Property | Pidotimod | HNP-1 |
|---|---|---|
| Category | Immune Support | Immune Support |
| Full Name | 3-L-Pyroglutamyl-L-Thiazolidine-4-Carboxylic Acid | Human Neutrophil Peptide 1 (Alpha-Defensin 1) |
| Molecular Weight | 244.27 Da | 3443 Da |
| Half-Life | 3-4 h | Minutes to hours; protease-sensitive |
| Amino Acids | 2 | 30 |
| Typical Dose | 400-800 mg/day | Research use only; no approved human dose |
| Route | Oral | Topical / Research parenteral |
| Purity | ≥98% | ≥98% |
| Studies Count | 200 | 610 |
| Research Status | Clinical | Pre-clinical |
Pidotimod Benefits
- ✓oral-immune-support
- ✓respiratory-infection-adjunct
- ✓innate-immunity
- ✓adaptive-immunity-support
HNP-1 Benefits
- ✓neutrophil-derived antimicrobial defense
- ✓broad pathogen killing
- ✓immune cell signaling
- ✓mucosal protection
Pidotimod Dosing
400 mg PO BID|typically 15-30 days|repeated seasonal cycles in studies
HNP-1 Dosing
0.1–10 µM in vitro|1–5 mg/kg in animal models|No established human dose
Pidotimod Side Effects
- ⚠nausea
- ⚠diarrhea
- ⚠rash
HNP-1 Side Effects
- ⚠membrane toxicity at high concentrations
- ⚠short in vivo stability
- ⚠potential inflammation amplification
Research Overview
Pidotimod
Pidotimod has human data in recurrent infections, especially where immune stimulation or reduced infection frequency is the target. Published work commonly reports improvements in phagocyte function, mucosal defense, and fewer respiratory infection episodes.
HNP-1
HNP-1 has been studied as a key component of neutrophil-mediated host defense against bacteria, fungi, and some enveloped viruses. Literature also reports immunomodulatory effects, including impacts on chemotaxis, cytokine release, and barrier defense.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.